ArticleExperimental hematology2012
Role of tumor suppressor p53 in megakaryopoiesis and platelet function.
Article in Experimental hematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 40 citations in OpenAlex.
- Unraveling the role ofHemaSphere · 2026Review
- Role of the mechanotransductor PIEZO1 in megakaryocyte differentiation.Journal of cellular and molecular medicine · 2024Article
- Article
- miR-486-5p and miR-22-3p Enable Megakaryocytic Differentiation of Hematopoietic Stem and Progenitor Cells without Thrombopoietin.International journal of molecular sciences · 2022Article
- The Y14-p53 regulatory circuit in megakaryocyte differentiation and thrombocytopenia.iScience · 2021Article
- Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding.Haematologica · 2020Review
- Trp53 regulates platelets in bone marrow via the PI3K pathway.Experimental and therapeutic medicine · 2020Article
- Suppressive effects of anagrelide on cell cycle progression and the maturation of megakaryocyte progenitor cell lines in human induced pluripotent stem cells.Haematologica · 2020Article
- Article
- Human megakaryocytic microparticles induce de novo platelet biogenesis in a wild-type murine model.Blood advances · 2020Article
- Epigenetic regulation of megakaryocytic and erythroid differentiation by PHF2 histone demethylase.Journal of cellular physiology · 2018Article
- Article
- The Hippo-p53 pathway in megakaryopoiesis.Haematologica · 2016Article
- Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.Current hematologic malignancy reports · 2016Review
- Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint.Haematologica · 2016Article
- P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis.Oncotarget · 2016Article
- Megakaryocytic Maturation in Response to Shear Flow Is Mediated by the Activator Protein 1 (AP-1) Transcription Factor via Mitogen-activated Protein Kinase (MAPK) Mechanotransduction.The Journal of biological chemistry · 2016Article
- Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms.Journal of clinical pathology · 2016Article
- Hoxa10 null animals exhibit reduced platelet biogenesis.British journal of haematology · 2016Article
- Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Leukemia · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
The pathobiological role of p53 has been widely studied, however, its role in normophysiology is relatively unexplored. We previously showed that p53 knock-down increased ploidy in megakaryocytic cultures. This study aims to examine the effect of p53 loss on in vivo megakaryopoiesis, platelet production, and function, and to investigate the basis for greater ploidy in p53(-/-) megakaryocytic cultures. Here, we used flow cytometry to analyze ploidy, DNA synthesis, and apoptosis in murine cultured and bone marrow megakaryocytes following thrombopoietin administration and to analyze fibrinogen binding to platelets in vitro. Culture of p53(-/-) marrow cells for 6 days with thrombopoietin gave rise to 1.7-fold more megakaryocytes, 26.1% ± 3.6% of which reached ploidy classes ≥64 N compared to 8.2% ± 0.9% of p53(+/+) megakaryocytes. This was due to 30% greater DNA synthesis in p53(-/-) megakaryocytes and 31% greater apoptosis in p53(+/+) megakaryocytes by day 4 of culture. Although the bone marrow and spleen steady-state megakaryocytic content and ploidy were similar in p53(+/+) and p53(-/-) mice, thrombopoietin administration resulted in increased megakaryocytic polyploidization in p53(-/-) mice. Although their platelet counts were normal, p53(-/-) mice exhibited significantly longer bleeding times and p53(-/-) platelets were less sensitive than p53(+/+) platelets to agonist-induced fibrinogen binding and P-selectin secretion. In summary, our in vivo and ex vivo studies indicate that p53 loss leads to increased polyploidization during megakaryopoiesis. Our findings also suggest for the first time a direct link between p53 loss and the development of fully functional platelets resulting in hemostatic deficiencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.